HOOKIPA Pharma (HOOK) Competitors

$1.19 0.00 (0.00%)

As of 05/15/2026 09:54 AM Eastern

HOOK vs. ENTX, DWTX, TIL, INKT, and IXHL

Should you buy HOOKIPA Pharma stock or one of its competitors? MarketBeat compares HOOKIPA Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with HOOKIPA Pharma include Entera Bio (ENTX), Dogwood Therapeutics (DWTX), Instil Bio (TIL), MiNK Therapeutics (INKT), and Incannex Healthcare (IXHL). These companies are all part of the "pharmaceutical products" industry.

How does HOOKIPA Pharma compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

Entera Bio currently has a consensus price target of $9.00, suggesting a potential upside of 631.11%. Given Entera Bio's stronger consensus rating and higher probable upside, analysts plainly believe Entera Bio is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 10.4% of Entera Bio shares are held by insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Entera Bio had 5 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 5 mentions for Entera Bio and 0 mentions for HOOKIPA Pharma. Entera Bio's average media sentiment score of 1.18 beat HOOKIPA Pharma's score of 0.00 indicating that Entera Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Entera Bio	Positive
HOOKIPA Pharma	Neutral

Entera Bio has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Entera Bio's return on equity of -83.31% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-83.31%	-70.83%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

Entera Bio has higher earnings, but lower revenue than HOOKIPA Pharma. Entera Bio is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	$40K	1,514.75	-$11.44M	-$0.27	N/A
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A

Entera Bio has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

Entera Bio beats HOOKIPA Pharma on 13 of the 16 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Dogwood Therapeutics?

HOOKIPA Pharma (NASDAQ:HOOK) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Dogwood Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. HOOKIPA Pharma's return on equity of -120.09% beat Dogwood Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Dogwood Therapeutics	N/A	-358.33%	-30.47%

Dogwood Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A
Dogwood Therapeutics	N/A	N/A	-$34.26M	-$10.60	N/A

Dogwood Therapeutics has a consensus target price of $12.00, indicating a potential upside of 598.08%. Given Dogwood Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dogwood Therapeutics is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Dogwood Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Dogwood Therapeutics had 7 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 7 mentions for Dogwood Therapeutics and 0 mentions for HOOKIPA Pharma. Dogwood Therapeutics' average media sentiment score of 0.62 beat HOOKIPA Pharma's score of 0.00 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Dogwood Therapeutics	Positive

HOOKIPA Pharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market. Comparatively, Dogwood Therapeutics has a beta of 1.68, meaning that its stock price is 68% more volatile than the broader market.

63.9% of HOOKIPA Pharma shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 3.3% of HOOKIPA Pharma shares are owned by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Dogwood Therapeutics beats HOOKIPA Pharma on 10 of the 15 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Instil Bio?

Instil Bio (NASDAQ:TIL) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

Instil Bio has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Instil Bio's return on equity of -38.84% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Instil Bio	N/A	-38.84%	-21.99%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

60.6% of Instil Bio shares are held by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are held by institutional investors. 47.0% of Instil Bio shares are held by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

HOOKIPA Pharma has higher revenue and earnings than Instil Bio. Instil Bio is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A

In the previous week, Instil Bio had 3 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 3 mentions for Instil Bio and 0 mentions for HOOKIPA Pharma. Instil Bio's average media sentiment score of 0.96 beat HOOKIPA Pharma's score of 0.00 indicating that Instil Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Instil Bio	Positive
HOOKIPA Pharma	Neutral

Instil Bio currently has a consensus price target of $66.00, indicating a potential upside of 705.86%. Given Instil Bio's stronger consensus rating and higher probable upside, research analysts clearly believe Instil Bio is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Instil Bio	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Instil Bio has a beta of 1.94, suggesting that its stock price is 94% more volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market.

Summary

Instil Bio beats HOOKIPA Pharma on 9 of the 14 factors compared between the two stocks.

How does HOOKIPA Pharma compare to MiNK Therapeutics?

HOOKIPA Pharma (NASDAQ:HOOK) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

MiNK Therapeutics has lower revenue, but higher earnings than HOOKIPA Pharma. MiNK Therapeutics is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.97	N/A

MiNK Therapeutics has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. MiNK Therapeutics' return on equity of 0.00% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
MiNK Therapeutics	N/A	N/A	-118.05%

HOOKIPA Pharma has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, MiNK Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market.

63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by company insiders. Comparatively, 22.5% of MiNK Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, MiNK Therapeutics had 14 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 14 mentions for MiNK Therapeutics and 0 mentions for HOOKIPA Pharma. MiNK Therapeutics' average media sentiment score of 0.29 beat HOOKIPA Pharma's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
MiNK Therapeutics	Neutral

MiNK Therapeutics has a consensus price target of $35.00, indicating a potential upside of 247.22%. Given MiNK Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe MiNK Therapeutics is more favorable than HOOKIPA Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MiNK Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Summary

MiNK Therapeutics beats HOOKIPA Pharma on 11 of the 16 factors compared between the two stocks.

How does HOOKIPA Pharma compare to Incannex Healthcare?

Incannex Healthcare (NASDAQ:IXHL) and HOOKIPA Pharma (NASDAQ:HOOK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incannex Healthcare	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Incannex Healthcare has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Incannex Healthcare's return on equity of -88.67% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incannex Healthcare	N/A	-88.67%	-83.39%
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%

In the previous week, Incannex Healthcare had 8 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 8 mentions for Incannex Healthcare and 0 mentions for HOOKIPA Pharma. Incannex Healthcare's average media sentiment score of 1.00 beat HOOKIPA Pharma's score of 0.00 indicating that Incannex Healthcare is being referred to more favorably in the media.

Company	Overall Sentiment
Incannex Healthcare	Positive
HOOKIPA Pharma	Neutral

Incannex Healthcare has a beta of 7.22, meaning that its stock price is 622% more volatile than the broader market. Comparatively, HOOKIPA Pharma has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

HOOKIPA Pharma has higher revenue and earnings than Incannex Healthcare. Incannex Healthcare is trading at a lower price-to-earnings ratio than HOOKIPA Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incannex Healthcare	$90K	490.72	-$46.88M	-$8.41	N/A
HOOKIPA Pharma	$9.35M	1.57	-$43.50M	-$3.54	N/A

0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 63.9% of HOOKIPA Pharma shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by company insiders. Comparatively, 3.3% of HOOKIPA Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Incannex Healthcare and HOOKIPA Pharma tied by winning 7 of the 14 factors compared between the two stocks.

Get HOOKIPA Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HOOK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HOOK vs. The Competition

Export

Metric	HOOKIPA Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$14.67M	$3.25B	$6.22B	$12.13B
Dividend Yield	N/A	2.34%	2.80%	5.30%
P/E Ratio	-0.20	18.40	20.64	25.10
Price / Sales	1.57	275.46	545.20	69.82
Price / Cash	N/A	55.27	27.48	37.27
Price / Book	0.28	6.51	9.67	6.60
Net Income	-$43.50M	$24.35M	$3.56B	$335.32M
7 Day Performance	0.85%	-3.85%	-2.19%	-2.06%
1 Month Performance	3.48%	-4.30%	-2.97%	-1.44%
1 Year Performance	-23.72%	55.85%	30.66%	27.53%

HOOKIPA Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HOOK HOOKIPA Pharma	N/A	$1.19 flat	N/A	-23.7%	$14.67M	$9.35M	N/A	160	Gap Down
ENTX Entera Bio	3.7521 of 5 stars	$1.25 +6.8%	$9.00 +620.0%	-37.9%	$57.59M	$40K	N/A	20	Positive News
DWTX Dogwood Therapeutics	2.2068 of 5 stars	$1.70 +0.6%	$12.00 +605.9%	-65.6%	$56.45M	N/A	N/A	5	News Coverage Earnings Report Short Interest Increase Gap Up
TIL Instil Bio	2.2509 of 5 stars	$8.10 -0.4%	$66.00 +714.8%	-44.8%	$55.14M	N/A	N/A	410	Positive News Earnings Report Analyst Downgrade
INKT MiNK Therapeutics	2.497 of 5 stars	$11.41 +4.2%	$35.00 +206.7%	+42.2%	$54.55M	N/A	N/A	30	Earnings Report Analyst Upgrade Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HOOK) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HOOKIPA Pharma (HOOK) Competitors

HOOK vs. ENTX, DWTX, TIL, INKT, and IXHL

How does HOOKIPA Pharma compare to Entera Bio?

Summary

How does HOOKIPA Pharma compare to Dogwood Therapeutics?

Summary

How does HOOKIPA Pharma compare to Instil Bio?

Summary

How does HOOKIPA Pharma compare to MiNK Therapeutics?

Summary

How does HOOKIPA Pharma compare to Incannex Healthcare?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOOK vs. The Competition

HOOKIPA Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HOOKIPA Pharma (HOOK) Competitors

HOOK vs. ENTX, DWTX, TIL, INKT, and IXHL

How does HOOKIPA Pharma compare to Entera Bio?

Do analysts rate ENTX or HOOK?

Do insiders and institutionals have more ownership in ENTX or HOOK?

Does the media refer more to ENTX or HOOK?

Is ENTX or HOOK more profitable?

Which has higher earnings & valuation, ENTX or HOOK?

Which has more risk & volatility, ENTX or HOOK?

Summary

How does HOOKIPA Pharma compare to Dogwood Therapeutics?

Is HOOK or DWTX more profitable?

Which has preferable earnings and valuation, HOOK or DWTX?

Do analysts recommend HOOK or DWTX?

Does the media prefer HOOK or DWTX?

Which has more volatility & risk, HOOK or DWTX?

Do institutionals & insiders have more ownership in HOOK or DWTX?

Summary

How does HOOKIPA Pharma compare to Instil Bio?

Is TIL or HOOK more profitable?

Do institutionals and insiders have more ownership in TIL or HOOK?

Which has stronger earnings and valuation, TIL or HOOK?

Does the media refer more to TIL or HOOK?

Do analysts recommend TIL or HOOK?

Which has more volatility and risk, TIL or HOOK?

Summary

How does HOOKIPA Pharma compare to MiNK Therapeutics?

Which has better valuation & earnings, HOOK or INKT?

Is HOOK or INKT more profitable?

Which has more risk & volatility, HOOK or INKT?

Do institutionals and insiders believe in HOOK or INKT?

Does the media refer more to HOOK or INKT?

Do analysts rate HOOK or INKT?

Summary

How does HOOKIPA Pharma compare to Incannex Healthcare?

Do analysts prefer IXHL or HOOK?

Is IXHL or HOOK more profitable?

Does the media prefer IXHL or HOOK?

Which has more risk and volatility, IXHL or HOOK?

Which has better valuation and earnings, IXHL or HOOK?

Do insiders and institutionals have more ownership in IXHL or HOOK?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOOK vs. The Competition

HOOKIPA Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools